Will Worse Side Effects for Moderna's Vaccine Boost Pfizer's Fortunes?

Johnson & Johnson won't be able to supply as many doses of its vaccine in the next few weeks as originally hoped due to manufacturing issues at a contractor's facility. With these headwinds for J&J, the vaccines developed by Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) (with its partner BioNTech (NASDAQ: BNTX)) are in high demand. Both Moderna and Pfizer/BioNTech have secured supply deals with the U.S. for 300 million doses each.